Omega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: Randomized clinical trial

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.contributorThe Forsyth Institute-
Autor(es): dc.contributorGuarulhos University-
Autor(es): dc.creatorCastro dos Santos, Nidia C. [UNESP]-
Autor(es): dc.creatorAndere, Naira M. R. B. [UNESP]-
Autor(es): dc.creatorAraujo, Cássia F. [UNESP]-
Autor(es): dc.creatorde Marco, Andrea C. [UNESP]-
Autor(es): dc.creatorKantarci, Alpdogan-
Autor(es): dc.creatorVan Dyke, Thomas E.-
Autor(es): dc.creatorSantamaria, Mauro P. [UNESP]-
Data de aceite: dc.date.accessioned2022-02-22T00:26:20Z-
Data de disponibilização: dc.date.available2022-02-22T00:26:20Z-
Data de envio: dc.date.issued2020-12-11-
Data de envio: dc.date.issued2020-12-11-
Data de envio: dc.date.issued2019-12-31-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1002/JPER.19-0613-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/199050-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/199050-
Descrição: dc.descriptionBackground: Supplementation with omega-3 polyunsaturated fatty acids (ω-3 PUFA) and low-dose aspirin (ASA) have been proposed as a host modulation regimen to control chronic inflammatory diseases. The aim of this study was to investigate the clinical and immunological impact of orally administered ω-3 PUFA and ASA as adjuncts to periodontal debridement for the treatment of periodontitis in patients type 2 diabetes. Methods: Seventy-five patients (n = 25/group) were randomly assigned to receive placebo and periodontal debridement (CG), ω-3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months) after periodontal debridement (test group [TG]1), or ω-3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months) before periodontal debridement (TG2). Periodontal parameters and GCF were collected at baseline (t0), 3 months after periodontal debridement and ω-3 PUFA + ASA or placebo for TG1 and CG (t1), after ω-3 PUFA + ASA (before periodontal debridement) for TG2 (t1), and 6 months after periodontal debridement (all groups) (t2). GCF was analyzed for cytokine levels by multiplex ELISA. Results: Ten patients (40%) in TG1 and nine patients (36%) in TG2 achieved the clinical endpoint for treatment (less than or equal to four sites with probing depth ≥ 5 mm), as opposed to four (16%) in CG. There was clinical attachment gain in moderate and deep pockets for TG1. IFN-γ and interleukin (IL)-8 levels decreased over time for both test groups. IL-6 levels were lower for TG1. HbA1c levels reduced for TG1. Conclusion: Adjunctive ω-3 and ASA after periodontal debridement provides clinical and immunological benefits to the treatment of periodontitis in patients with type 2 diabetes.-
Descrição: dc.descriptionDivision of Periodontics Unesp – São Paulo State University Institute of Science and Technology-
Descrição: dc.descriptionCenter for Clinical and Translational Research The Forsyth Institute-
Descrição: dc.descriptionDental Research Division Guarulhos University-
Descrição: dc.descriptionDivision of Periodontics Unesp – São Paulo State University Institute of Science and Technology-
Idioma: dc.languageen-
Relação: dc.relationJournal of Periodontology-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectaspirin-
Palavras-chave: dc.subjectdiabetes-
Palavras-chave: dc.subjectimmunomodulation-
Palavras-chave: dc.subjectinflammation-
Palavras-chave: dc.subjectomega-3 fatty acids-
Palavras-chave: dc.subjectperiodontitis-
Título: dc.titleOmega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: Randomized clinical trial-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.